ArticleScience advances2022
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 113 citations in OpenAlex.
- Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.Nature cancer · 2024Trial
- Glutamine metabolism in health and disease.Signal transduction and targeted therapy · 2026Review
- Glutamine Metabolism in Health and Diseases.MedComm · 2026Review
- Maternal hyperglycemia-induced O-GlcNAcylation of CaMKIIδ promotes mtDNA release and cardiac remodeling in offspring.Nature communications · 2026Article
- 70 Years of DON and Beyond: Glutaminase Inhibition as a Synergistic Strategy in Cancer Combination Therapy.Pharmaceutics · 2026Review
- Reprogramming macrophage immunometabolism via glutamine antagonism potentiates colorectal cancer therapy in mice.Nature communications · 2026Article
- Ketogenic diet as a metabolic vehicle enhancing the therapeutic efficacy of mebendazole and devimistat in juvenile syngeneic high-grade glioma.Cell reports. Medicine · 2026Article
- Dynamic remodeling of amino acid metabolism in tumor-associated macrophages: Fueling immunosuppression, reshaping tumor niches, and unlocking metabolic checkpoints.Journal of advanced research · 2026Review
- Metabolites as signalling molecules in the tumour immune microenvironment.Nature reviews. Immunology · 2026Review
- Single-cell RNA sequencing reveals that host Glutamine Metabolism Inhibition Enhances Macrophage Phagocytosis ofbioRxiv : the preprint server for biology · 2026Article
- A Boronic Acid-Based Glutamine Analog Forms a Covalent Adduct with Kidney-Type Glutaminase and Suppresses Triple-Negative Breast Cancer Cell Proliferation.Biomedicines · 2026Article
- Metabolic pattern changes of macrophages during cancer development and progression.Journal of translational medicine · 2026Review
- Overview of glutamine metabolism in stromal components of the tumor microenvironment and potential anti-tumor therapies.Genes & diseases · 2026Review
- Decoding the Hexosamine Biosynthesis Pathway: Implications for Novel Therapeutic Strategies in Sarcoma.Journal of cellular physiology · 2026Review
- Targeting glutamine metabolism to modulate macrophage functions in the tumor microenvironment.Discover oncology · 2026Review
- Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Review
- Tumor-intrinsic metabolic pathways essential for tumorigenesis and resistance to anti-PD1 in oncogenic Kras-driven lung adenocarcinoma.Cancer & metabolism · 2026Article
- PHGDH is a targetable driver of PDAC progression.bioRxiv : the preprint server for biology · 2026Article
- Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma.Cancer research · 2026Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 2 countries.
Rana RaisJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-4059-2453
Kathryn M LembergJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-1511-9322
Lukáš TenoraJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-6982-3545
Matthew L ArwoodThe Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-4737-9786
Arindom PalJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-3005-2728
Jesse AltJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-5440-7891
Ying WuJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-6288-4636
Jenny LamJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-7915-3530
Joanna Marie H AguilarJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-0499-1927
Liang ZhaoDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-2126-6778
Diane E PetersJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-4185-6203
Carolyn TallonJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-4888-547X
Rajeev PandeyDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-1368-323X
Ajit G ThomasJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-5922-5050
Ranjeet P DashJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Tanguy SeiwertDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-7919-8272
Pavel MajerInstitute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic v.v.i., Prague 16000, Czech Republic.ORCID 0000-0002-1804-6934
Robert D LeoneDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-2983-8531
Jonathan D PowellDepartment of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-0850-2852
Barbara S SlusherJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-9814-4157
Johns Hopkins University · USBloomberg (United States) · USCzech Academy of Sciences · CZ
Funding
LAB RESEARCH TRAINING IN PEDIATRIC ONCOLOGY-HEMATOLOGYT32CA060441 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN D FRIEDMAN · 1993 to 2026
$14.9MCell-targeted glutamine antagonists as a novel therapy for lymphomaR01CA229451 · NCI · JOHNS HOPKINS UNIVERSITY · PI SLUSHER, BARBARA STAUCH · 2018 to 2022
$2.3MGlutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer TherapyR01CA193895 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S., LE, ANNE · 2016 to 2020
$2.1MTargeting Tumor Metabolism as a Means of Enhancing ImmunotherapyR01CA226765 · NCI · JOHNS HOPKINS UNIVERSITY · PI LEONE, ROBERT DAVID · 2019 to 2023
$1.9MNovel brain penetrant metabolic inhibitors to treat MYC-driven medulloblastomaR01NS103927 · NINDS · JOHNS HOPKINS UNIVERSITY · PI RAABE, ERIC HUTTON, SLUSHER, BARBARA STAUCH · 2018 to 2021
$1.6MNCI NIH HHS R01 CA193895NCI NIH HHS R01 CA226765NCI NIH HHS R01 CA229451NCI NIH HHS T32 CA060441NINDS NIH HHS R01 NS103927
Abstract
6-Diazo-5-oxo-l-norleucine (DON) is a glutamine antagonist that suppresses cancer cell metabolism but concurrently enhances the metabolic fitness of tumor CD8
Indexed as
NeoplasmsProdrugsCD8-Positive T-LymphocytesDiazooxonorleucineEnzyme InhibitorsGlutamineHumansDiazooxonorleucineEnzyme InhibitorsGlutamineProdrugs
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.